New combo therapy aims to wipe out hidden leukemia cells in High-Risk patients

NCT ID NCT03128879

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study is for people with high-risk chronic lymphocytic leukemia (CLL) who have been on ibrutinib or acalabrutinib for at least a year but still have detectable disease. Researchers want to see if adding venetoclax for 12 cycles can clear remaining leukemia cells from the bone marrow. The trial will enroll 90 participants at a single center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax (added to ibrutinib or acalabrutinib)
What this could lead to: If successful, this combination could help high-risk CLL patients achieve undetectable minimal residual disease, potentially leading to longer remission and better disease control.
What could go wrong: This is a single-center phase II study with only 90 participants, so results may not apply broadly. Adding venetoclax may increase side effects like low blood counts or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.